![ODAC gives thumbs down to single-arm trial of two-drug combination for multiple myeloma Committee focuses on meaning of equipoise, accelerated approval, confirmatory trials](https://cdn.cancerletter.com/media/2019/03/odac-web.jpg)
![ODAC gives thumbs down to single-arm trial of two-drug combination for multiple myeloma Committee focuses on meaning of equipoise, accelerated approval, confirmatory trials](https://cdn.cancerletter.com/media/2019/03/odac-web.jpg)
Cover Story
It's not just the absence of a randomized trial that prompted the FDA Oncologic Drugs Advisory Committee to recommend against an accelerated approval of the Karyopharm Therapeutics Inc. drug selinexor for late-stage multiple myeloma.
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Drugs & Targets
Trending Stories
- Before the Olympics were smoke-free, tobacco brand deals ran rampant
- Kamala Harris widely expected to continue Cancer Moonshot; Conservatives present their vision in Project 2025
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications
- Better oncology drug management could lead to improved outcomes, lower costs
- Tweaking the existing systems is not the answer to drug shortages